280 related articles for article (PubMed ID: 2757026)
21. [Influence of iron metabolism on the efficacy of r-HuEPO (recombinant human erythropoietin) treatment of anemia in children on hemodialysis].
Pela I; Lavoratti GC; Materassi M; Burgio G; Bartolozzi G
Pediatr Med Chir; 1991; 13(5):475-7. PubMed ID: 1788107
[TBL] [Abstract][Full Text] [Related]
22. Adverse effects of therapy for the correction of anemia in hemodialysis patients.
Watson AJ
Semin Nephrol; 1989 Mar; 9(1 Suppl 1):30-4. PubMed ID: 2648519
[TBL] [Abstract][Full Text] [Related]
23. An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin.
Markowitz GS; Kahn GA; Feingold RE; Coco M; Lynn RI
Clin Nephrol; 1997 Jul; 48(1):34-40. PubMed ID: 9247776
[TBL] [Abstract][Full Text] [Related]
24. [Initial response to treatment with erythropoietin in anemia caused by chronic renal insufficiency].
Sánchez Casajús A; Barrau J; Gómez Alamillo C; Jaurrieta F
Sangre (Barc); 1990 Feb; 35(1):82-4. PubMed ID: 2333585
[TBL] [Abstract][Full Text] [Related]
25. Characterization of the anaemia of chronic renal failure and the mode of its correction by a preparation of human erythropoietin (r-HuEPO). An investigation of the pharmacokinetics of intravenous erythropoietin and its effects on erythrokinetics.
Cotes PM; Pippard MJ; Reid CD; Winearls CG; Oliver DO; Royston JP
Q J Med; 1989 Feb; 70(262):113-37. PubMed ID: 2594953
[TBL] [Abstract][Full Text] [Related]
26. Overview of anemia associated with chronic renal disease: primary and secondary mechanisms.
Paganini EP
Semin Nephrol; 1989 Mar; 9(1 Suppl 1):3-8. PubMed ID: 2648518
[TBL] [Abstract][Full Text] [Related]
27. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
Li H; Wang SX
Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
[TBL] [Abstract][Full Text] [Related]
28. Human recombinant erythropoietin treatment in transfusion dependent anemic patients on maintenance hemodialysis.
Zehnder C; Blumberg A
Clin Nephrol; 1989 Feb; 31(2):55-9. PubMed ID: 2920469
[TBL] [Abstract][Full Text] [Related]
29. [Iron stores in patients with chronic kidney failure treated with recombinant human erythropoietin].
Cermák J; Gregora E; Lachmanová J; Brabec V
Vnitr Lek; 1994 Mar; 40(3):174-8. PubMed ID: 8184571
[TBL] [Abstract][Full Text] [Related]
30. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in hemodialysis patients.
Chen YC; Hung SC; Tarng DC
Am J Kidney Dis; 2006 Jun; 47(6):1036-44. PubMed ID: 16731299
[TBL] [Abstract][Full Text] [Related]
31. Effect of recombinant human erythropoietin on iron balance in maintenance hemodialysis: theoretical considerations, clinical experience and consequences.
Grützmacher P; Tsobanelis T; Roth P; Werner E; Vlachojannis J; Kaltwasser J; Kurz P; Scheuermann EH; Schoeppe W
Clin Nephrol; 1992; 38 Suppl 1():S92-7. PubMed ID: 1295714
[TBL] [Abstract][Full Text] [Related]
32. Recombinant human erythropoietin: impact on brain and cognitive function, exercise tolerance, sexual potency, and quality of life.
Nissenson AR
Semin Nephrol; 1989 Mar; 9(1 Suppl 2):25-31. PubMed ID: 2669083
[TBL] [Abstract][Full Text] [Related]
33. Use of recombinant human erythropoietin for management of anemia in dogs and cats with renal failure.
Cowgill LD; James KM; Levy JK; Browne JK; Miller A; Lobingier RT; Egrie JC
J Am Vet Med Assoc; 1998 Feb; 212(4):521-8. PubMed ID: 9491159
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin.
Wingard RL; Parker RA; Ismail N; Hakim RM
Am J Kidney Dis; 1995 Mar; 25(3):433-9. PubMed ID: 7872321
[TBL] [Abstract][Full Text] [Related]
35. The efficiency of fractionated parenteral iron treatment in CAPD patients.
Akcicek F; Ozkahya M; Cirit M; Ok E; Unsal A; Toz H; Celik A; Atabay G; Basci A
Adv Perit Dial; 1997; 13():109-12. PubMed ID: 9360661
[TBL] [Abstract][Full Text] [Related]
36. Infusion of total dose iron versus oral iron supplementation in ambulatory peritoneal dialysis patients: a prospective, cross-over trial.
Ahsan N
Adv Perit Dial; 2000; 16():80-4. PubMed ID: 11045266
[TBL] [Abstract][Full Text] [Related]
37. Management of renal anemia.
Peco-Antic A
Turk J Pediatr; 2005; 47 Suppl():19-27. PubMed ID: 15884663
[TBL] [Abstract][Full Text] [Related]
38. [Treatment of anemia in patients with renal failure using erythropoietin obtained by genetic recombination].
Wiecek A; Kokot F; Grzeszczak W; Klin M
Pol Tyg Lek; 1990 Sep 17-24; 45(38-39):782-6. PubMed ID: 2095546
[TBL] [Abstract][Full Text] [Related]
39. [Individual differences in the efficacy of Recormon in patients with terminal kidney failure. The role of iron deficiency].
Nikolaev AIu; Klepikov PV; Lashutin SV; Kondakhchan MA; Rogov VA; Trofimova EI
Ter Arkh; 1993; 65(6):45-8. PubMed ID: 8378849
[TBL] [Abstract][Full Text] [Related]
40. Correction of anaemia in haemodialysis patients with recombinant human erythropoietin.
Boran M; Dalva I; Yazicioğlu A; Akbay E; Cetin S
Int Urol Nephrol; 1993; 25(2):197-203. PubMed ID: 8365853
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
